Lipid Nanoparticle mRNA Delivery for Safer CAR-T Cell Engineering

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cell therapy methods, such as CAR-T cell therapy, face challenges including high costs due to ex vivo cell culture, safety concerns from lentiviral use, and severe side effects, necessitating improved compounds and methods for delivering nucleic acids to enhance stability, internalization, and reduce cytotoxicity.

Innovation Solution

Development of novel mRNA compositions, including self-amplifying and modified mRNA, circular mRNA, and lipid nanoparticle formulations with ionizable lipids to enhance transfection efficiency and stability, facilitating in vivo and ex vivo delivery of therapeutic polypeptides like CARs, reducing safety issues and costs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If lentiviral vectors are used to genetically modify T cells ex vivo, then CAR expression is achieved, but safety concerns and severe side effects occur

Engineering Contradiction:

ImprovesafetyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the delivery vehicle from lentiviral vectors to lipid nanoparticle-encapsulated mRNA, fundamentally altering the genetic modification approach. This parameter change eliminates integration into host genome, thereby reducing safety concerns and side effects while maintaining CAR expression capability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces lipid nanoparticles as an intermediary delivery system to transport mRNA into T cells. This intermediary approach replaces direct lentiviral transduction, achieving genetic modification without the associated safety risks and cytotoxic effects

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If autologous T cells are cultured ex vivo for CAR-T therapy, then antigen-specific destruction capability is achieved, but costs increase significantly

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidcost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts the genetic modification step from the complex ex vivo cell culture process by delivering mRNA directly in vivo. This eliminates the need for expensive ex vivo expansion facilities, animal-free media, and prolonged culture procedures, thereby significantly reducing manufacturing costs while maintaining therapeutic efficacy

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If conventional mRNA is used for transfection, then gene delivery is achieved, but stability and transfection efficiency are insufficient

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidmRNA stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent creates a composite delivery system by encapsulating mRNA within lipid nanoparticles. This composite structure protects mRNA from degradation, enhances cellular uptake, and improves overall transfection efficiency and stability compared to conventional naked mRNA delivery

Inventive Principle:

Principle #40Composite materials

4Productivity

If ionizable lipids are used in LNP formulations, then transfection efficiency improves, but cytotoxic effects may increase

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidcytotoxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent optimizes the ionizable lipid parameters including pKa value, chain length, and head group structure to achieve the right balance. By carefully adjusting these parameters, the LNP formulation maintains high transfection efficiency while minimizing cytotoxic effects through reduced membrane disruption and improved biocompatibility

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel mRNA and LNP compositions improve transfection efficiency, stability, and safety, enabling effective in vivo and ex vivo delivery of therapeutic polypeptides, thereby reducing costs and minimizing side effects in cell therapy treatments.

Implementation Method 1

LNP compositions comprising novel ionizable lipids, which improve stability, facilitate internalization

Methodology Applied

Scientific EffectEncapsulation:

Implementation Method 2

lipid nanoparticle (LNP) encapsulating a payload encoding at least one polypeptide of interest

Methodology Applied

Scientific EffectLipid nanoparticle delivery:

Implementation Method 3

novel ionizable lipids and lipid nanoparticles (LNPs)... facilitate internalization, and reduce safety concerns

Methodology Applied

Scientific EffectIonizable lipid interaction:

Data Source

PatentUS12551451B2Compositions and methods for delivering molecules

Publication Date: 2026.02.17 SUNVAX MRNA THERAPEUTICS INC

AI summary

Compositions comprising mRNA, self-amplifying mRNA (sa-mRNA), modified mRNA, or circular RNA constructs comprising a gene-of-interest, and lipids and LNPs for use in therapy are disclosed. A method of delivering a payload to immune cells ex vivo by contacting immune cells with a lipid nanoparticle (LNP) encapsulating a payload encoding at least one polypeptide of interest, wherein the polypeptide of interest is an antigen receptor or an antibody.